Clementia Pharmaceuticals Inc (NASDAQ:CMTA)’s share price reached a new 52-week high on Monday . The stock traded as high as $26.73 and last traded at $26.38, with a volume of 131024 shares trading hands. The stock had previously closed at $26.49.
Several research firms have weighed in on CMTA. Svb Leerink lowered shares of Clementia Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $26.00 target price on the stock. in a report on Tuesday, February 26th. Bloom Burton lowered shares of Clementia Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 26th. Robert W. Baird lowered shares of Clementia Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Monday, March 4th. Wedbush lowered shares of Clementia Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Monday, February 25th. Finally, ValuEngine upgraded shares of Clementia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, February 25th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Clementia Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $25.00.
The firm has a market capitalization of $1.00 billion, a P/E ratio of -3.32 and a beta of 0.64.
TRADEMARK VIOLATION WARNING: This article was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/clementia-pharmaceuticals-cmta-hits-new-1-year-high-at-26-73.html.
About Clementia Pharmaceuticals (NASDAQ:CMTA)
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.
Recommended Story: What is Depreciation?
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.